Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Stomach Neoplasms 34Carcinoma, Hepatocellular 33Carcinoma, Non-Small-Cell Lung 23Colorectal Neoplasms 16Esophageal Squamous Cell Carcinoma 12Lung Neoplasms 9Rectal Neoplasms 8Nasopharyngeal Carcinoma 8Esophageal Neoplasms 6Cholangiocarcinoma 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Carcinoma 3Breast Neoplasms 3Spinocerebellar Degenerations 2Sarcoma 2Recurrence 2Nonsquamous Non-Small Cell Lung Cancer 2Neuroendocrine Tumors 2Lymphoma, T-Cell, Peripheral 2Locally Advanced Rectal Cancer 2

Interventions

Etoposide 3Dexamethasone 2Cyclophosphamide 2Alemtuzumab 2tocilizumab 1sintilimab 1pegaspargase 1Whole-Body Irradiation 1Vincristine 1Prednisone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Methotrexate 1Gemcitabine 1EPOCH protocol 1Doxorubicin 1Cytarabine 1Calcium Dobesilate 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphohistiocytosis, Hemophagocytic × sintilimab × Clear all
NCT05008666 2021-08-17

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Sun Yat-sen University

Phase 2 Unknown
37 enrolled
LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡